Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by B Monje
PP-026 Intranasal bevacizumab treatment on epistaxis in hereditary haemorrhagic telangiectasia: a case report
Background Hereditary haemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease, is a rare, vascular, autosomal dominant disorder. Telangiectasias and arteriovenous malformations (AVMs) of the lung, liver and CNS are vascular lesions present in HHT, most commonly causing epistaxis and gastrointestinal bleeding. The diagnosis is based on the Curaçao criteria. Recently, the epistaxis severity score (ESS) was created as a standardised measure to estimate the degree of epistaxis.
PS-063 Medication label design and patient safety: An interactive comparison test
Background According to the Institute of Medicine, inadequate medication labelling accounts for 33% of medication errors. As part of the institutional risk management strategy, in 2015 a multidisciplinary team redesigned the labels for hospital compounded preparations in order to comply with the recommendations issued by the Institute for Safe Medication Practices and to include route of administration colour coding. Purpose To develop a computer test for label design testing.
DI-022 Real life effectiveness and safety of lenalidomide in the treatment of multiple myeloma
Background In 2009, lenalidomide was included in our hospital formulary for the treatment of multiple myeloma (MM). Presently, real world data are fundamental in the evaluation of drugs. Purpose To assess the effectiveness and safety of lenalidomide for MM in clinical practice in a university hospital. Material and methods We carried out a retrospective, longitudinal, observational study which included all patients treated with lenalidomide for MM between January 2015 and August 2015.
CP-031 Clinical use of lenalidomide for the treatment of multiple myeloma
Background In April 2009, lenalidomide was included in the hospital formulary for the treatment of multiple myeloma (MM) in patients who had received at least one previous therapy. The recommended starting dose (25 mg of lenalidomide) should be adjusted according to clinical and laboratory findings. Purpose Our objective was to assess the prescription profile of lenalidomide in a tertiary hospital and compliance with the hospital formulary criteria.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with B
Contact B, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack